Want to see IN:LAURUSLABS full AI Analyst Report?
LAURUSLABS Stock Chart & Stats
₹1602.30
₹112.20(7.01%)
At close: 4:00 PM EDT
₹1602.30
₹112.20(7.01%)
Day’s Range― - ―
52-Week Range₹822.85 - ₹1,898.20
Previous CloseN/A
Volume7.99M
Average Volume (3M)107.31K
Market Cap
₹1.01T
Enterprise Value₹560.82K
Total Cash (Recent Filing)₹1.14B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)93.2
Beta0.95
Next Earnings
Oct 22, 2026EPS Estimate
5.58Next Dividend Ex-DateN/A
Dividend Yield0.11%
Share Statistics
EPS (TTM)20.25
Shares Outstanding540,312,200
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)10.11
Price to Sales (P/S)7.86
P/FCF Ratio137.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,700.00Price Target Upside6.10% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)24.69
Revenue Forecast (FY)₹83.34B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe return to revenue growth after a prior decline indicates resilient demand across Laurus Labs' API, finished-dose and CDMO activities. Sustained recovery would support better capacity utilization and provide a foundation for rebuilding earnings power.
Profitability ReboundThe sharp improvement in net margin and solid EBITDA margin show that profitability has recovered meaningfully. If maintained through product mix, pricing and operating execution, this can strengthen internal funding and improve resilience across business cycles.
Improving LeverageLower leverage reduces balance-sheet pressure and improves financial flexibility as Laurus Labs invests in manufacturing scale and capabilities. The rising equity base also provides a stronger cushion against volatility in pharmaceutical demand, margins or cash conversion.
Bears Say
Weak Free Cash FlowPersistently weak cash conversion suggests that capital expenditure and working-capital needs are absorbing a substantial share of accounting profits. This constrains funding flexibility for expansion, debt reduction and shareholder returns even while earnings recover.
Gross Margin CompressionThe sustained gap versus historical gross margins indicates that input costs, pricing pressure or product mix may be weighing on economics. Margin recovery is important because weaker gross profitability can limit the benefit of revenue growth and reduce earnings durability.
Uneven Growth ProfileThe recent rebound demonstrates resilience but also highlights variability in demand, product mix or customer activity. An uneven growth profile makes capacity planning and cash deployment less predictable and may delay a return to the stronger earnings trajectory seen in earlier periods.
Laurus Labs Ltd. News
LAURUSLABS FAQ
What was Laurus Labs Ltd.’s price range in the past 12 months?
Laurus Labs Ltd. lowest stock price was ₹822.85 and its highest was ₹1898.20 in the past 12 months.
What is Laurus Labs Ltd.’s market cap?
Laurus Labs Ltd.’s market cap is ₹1.01T.
When is Laurus Labs Ltd.’s upcoming earnings report date?
Laurus Labs Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 56 days.
How were Laurus Labs Ltd.’s earnings last quarter?
Laurus Labs Ltd. released its earnings results on Jul 24, 2026. The company reported ₹6.8 earnings per share for the quarter, beating the consensus estimate of ₹4.912 by ₹1.888.
Is Laurus Labs Ltd. overvalued?
According to Wall Street analysts Laurus Labs Ltd.’s price is currently Undervalued.
Does Laurus Labs Ltd. pay dividends?
Laurus Labs Ltd. pays a Semiannually dividend of ₹1.2 which represents an annual dividend yield of 0.11%. See more information on Laurus Labs Ltd. dividends here
What is Laurus Labs Ltd.’s EPS estimate?
Laurus Labs Ltd.’s EPS estimate is 5.58.
How many shares outstanding does Laurus Labs Ltd. have?
Laurus Labs Ltd. has 540,312,200 shares outstanding.
What happened to Laurus Labs Ltd.’s price movement after its last earnings report?
Laurus Labs Ltd. reported an EPS of ₹6.8 in its last earnings report, beating expectations of ₹4.912. Following the earnings report the stock price went up 2.168%.
Which hedge fund is a major shareholder of Laurus Labs Ltd.?
Currently, no hedge funds are holding shares in IN:LAURUSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Laurus Labs Ltd.
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
LAURUSLABS Stock 12 Month Forecast
Average Price Target
₹1,700.00
▲(6.10% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―







